Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
https://mobile.twitter.com/the_innova/status/1425706239007379456
Thanks Denny11,
I think we were going to get 1:1 accustem shares for TILS as well. Am I wrong?
Has anyone Got Accustem share for TILS on IG ?
I have received 1:1 for TLSA : Accustem on IG but nothing for TILS.
Wylie.E.Coyote, General public awareness is key to changing the Govt Position.
If public does not know that there is better test than Innova and or how bad Innova is, Govt would carry on like this, easy for them to ignore Avacta as nobody is asking questions.
I have spoken to many of my friends & Family and no one knows about Avacta or its Test or FDA warning of Innova
My local MP didn't know about Avacta or FDA warning on INNOVA. There is nothing in the TV News or Newspapers about this (I think).
I think we should be all be making a collective effort to raise awareness of Avacta test. ( I know some people on the board has written to their MP's and News channels).
What are your views on this please?
In my opinion main stream media is probably being stopped from exposing this as it might create panic in general public. Hopefully the Innova contract will not be renewed and new LFT from Avacta may replace this.
Zoom0001, Inaccurate test affects all of us whether AVACTA holders or not
----False-negative results may lead to delayed diagnosis or inappropriate treatment of SARS-CoV-2, which may cause patient harm including serious illness and death. False-negative results can also lead to further spread of the SARS-CoV-2 virus, including when presumed negative patients are grouped into cohorts in healthcare, long-term care, and other facilities based on false test results.
-----False-positive results could lead to a delay in both the correct diagnosis and the initiation of an appropriate treatment for the actual cause of patient illness, which could be another life-threatening disease that is not SARS-CoV-2. False-positive results could also lead to further spread of the SARS-CoV-2 virus when presumed positive patients are grouped into cohorts based on false test results.
Has anyone seen or heard any mention of FDA warning on Innova Test?
I have sent the following link to
https://www.fda.gov/medical-devices/safety-communications/stop-using-innova-sars-cov-2-antigen-rapid-qualitative-test-fda-safety-communication
news@skynews.com
radio@sky.uk
bbcnewsline@bbc.co.uk
This story should be in the News
https://twitter.com/MylesMcNulty/status/1402545939299045382
They also sold Burford
https://www.bbnbigbitenow.com/post/avacta-succeeding-more-than-many-believe
TRNS Number : 9702T
Tiziana Life Sciences PLC
30 March 2021
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
New York/London, 30 March 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug Administration (FDA) has allowed evaluation of nasal administration with Foralumab, a fully human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University, Boston, MA. This patient will be treated under an Individual Patient Expanded Access IND. This is the first time a nasally administered antibody will be administered to a patient with SPMS. The treatment is planned to start in the second quarter of 2021, and will continue for six months. Investigators at BWH will follow this patient with detailed routine safety, neurological, imaging and PET studies to evaluate microglial imaging. Modification of immunological and neurodegenerative markers is part of standard investigations that will be conducted at the BWH.
Previously, Tiziana completed a Phase 1 trial of a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) once a day dosing for 5 consecutive days with nasally administered Foralumab in healthy subjects. The treatment was well-tolerated with no drug-related safety issues reported at any doses up to 250 mg of the doses. Nasal foralumab was developed by Professor Howard Weiner at BWH.
Weiner commented, "Nasal anti-CD3 is an exciting, novel approach that has the ability to provide a safe treatment for a form of MS that has no effective treatment. We are pleased that the FDA has allowed us to treat a patient with SPMS who needs a better treatment option than is currently available."
Dr. Tanuja Chitnis, Professor of Neurology at Harvard Medical School and senior neurologist at the BWH, adds, "New treatments for progressive MS are urgently needed. Nasal Foralumab could revolutionize treatment for this disabling form of disease."
The company had previously reported positive data from the Clinical Study of Nasal Administration with Foralumab in COVID-19 patients in Brazil. Nasally administered Foralumab at 100 mg/day for consecutive 10 days treatment was found to be well-tolerated, and there were no apparent severe adverse events. The clinical data suggested that the treatment provided significant reduction of lung inflammation.
About Foralumab
Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases